Form 4: Disc Medicine Director Georges Gemayel Granted 10,000 Stock Options

Disc Medicine, Inc. Director Georges Gemayel was granted 10,000 stock options with an exercise price of $50.86, vesting based on future events.

Summary

• Georges Gemayel, a Director of Disc Medicine, Inc. (IRON), was granted 10,000 stock options.
• The grant date, which is also the earliest transaction date, is June 11, 2025.
• Each option has an exercise price of $50.86.
• The options will vest upon the earlier of the Company's 2026 annual meeting of stockholders or the one-year anniversary of the grant date (June 11, 2026), subject to Mr. Gemayel's continued service.
• The options expire on June 10, 2035.
• Following this transaction, Mr. Gemayel directly beneficially owns 10,000 stock options.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with shareholder value, generally viewed as a positive for corporate governance and long-term strategy.

Positives

• The grant of 10,000 stock options to Director Georges Gemayel aligns his interests with those of the company's shareholders, incentivizing long-term value creation.
• The options have a long expiration date of June 10, 2035, providing a sustained long-term incentive for the director.

Future Outlook

The stock options granted to Director Georges Gemayel are subject to future vesting conditions, specifically upon the earlier of the Company's 2026 annual meeting or the one-year anniversary of the grant date (June 11, 2026), contingent on his continued service.

Industry Context

This Form 4 filing reflects a standard practice within publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to incentivize directors and align their long-term interests with shareholder value through equity grants as a component of compensation.

Related Party Transactions

• Grant of 10,000 stock options to Georges Gemayel, a Director of Disc Medicine, Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns management's interests with shareholder value creation, potentially leading to better long-term performance and strategic decisions.

Next Steps

• Vesting of 10,000 stock options upon the earlier of the Company's 2026 annual meeting or June 11, 2026, subject to continued service.
• Potential exercise of stock options at $50.86 per share after vesting and before June 10, 2035.

Key Dates

Keywords

Disc Medicine, IRON, stock option, insider transaction, Form 4, Georges Gemayel, director compensation, equity grant